|View printer-friendly version|
|Vitae Pharmaceuticals to Present at IMMUNOLOGY 2016|
Poster to highlight positive Phase 1 data for RORγt inhibitor VTP-43742
VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORγt inhibitor with the potential to transform the treatment of multiple autoimmune disorders, including psoriasis, through the potent inhibition of IL-17 secretion from Th17 cells and blocking the action of IL-23.
The poster details are as follows:
Title: “Safety, tolerability, pharmacokinetics and pharmacodynamics or VTP-43742, a RORγt inhibitor, in normal healthy volunteers”
For more information on IMMUNOLOGY 2016, please visit http://www.immunology2016.org/.
Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae’s lead clinical assets include VTP-43742, an oral RORγt inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXRβ selective agonist being studied in patients with mild to moderate atopic dermatitis.
For additional information, please visit the company's website at www.vitaepharma.com.